This can be accomplished via HIF-1 inhibitors or by inhibition of MCT1 to force aerobic tumor cells to consume more glucose and less lactate and reduce glucose availability to the less well-perfused hypoxic cells. The gene discussed is HIF1A; the disease is neoplasm.